2 unknown, 1 recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Unknown 2, Recruiting 1 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow B-cell Acute Lymphocytic Leukemia: new trials by email Literature Review of B-cell Acute Lymphocytic Leukemia trials Research Report on B-cell Acute Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD - Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-07-11 | 2026-08-10 |
| CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. Cyclophosphamide, Fludarabine, CD19 CAR-T - B-cell Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Henan Cancer Hospital | 20 | 2017-08-16 | 2017-10-20 |
| CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia CD19 CAR-T cells - B-cell Acute Lymphocytic Leukemia | Phase 1 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 10 | 2017-03-01 | 2023-11-29 |
Burkitt Lymphoma (3) · Recurrence (1)
DNA Virus Infections (3) · Epstein-Barr Virus Infections (3) · Hemic and Lymphatic Diseases (3) · Herpesviridae Infections (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Infections (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Tumor Virus Infections (3)
CVAD protocol (1) · Cyclophosphamide (1) · Inotuzumab Ozogamicin (1) · blinatumomab (1) · fludarabine (1)
Henan Cancer Hospital (1) · M.D. Anderson Cancer Center (1) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (1)
China (2) · United States (1)
Elias Jabbour, MD (1) · Sheng-Li Xue, Ph.D (1)